Population-based study of giant cell tumor of bone in Sweden (1983–2011)

Amelio, Justyna; Rockberg, Julia; Hernandez, Rohini K.; Sobocki, Patrik; Stryker, Scott; Bach, Bruce Allen; Engellau, Jacob; Liede, Alexander

doi:10.1016/j.canep.2016.03.014

Cited by 43 publications

(53 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…GCTB is a locally aggressive tumor with the potential to metastasize to the lung . Although some of these metastases may spontaneously regress, treatment such as metastasectomy is needed in some cases .…”

Section: Discussionmentioning

confidence: 99%

“…GCTB is a locally aggressive tumor with the potential to metastasize to the lung. 17,18 Although some of these metastases may spontaneously regress, treatment such as metastasectomy is needed in some cases. 1 Prospective comparative study is necessary to verify the performance of chest radiography and CT in diagnosing lung metastasis from GCTB.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Surveillance for lung metastasis from giant cell tumor of bone

Rosario

Kim

Yun

et al. 2017

Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Surveillance for lung metastasis from giant cell tumor of bone

Rosario

Kim

Yun

et al. 2017

Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

“…It has been found that several types of bone lacerations involving osteoclastic giant cells such as; osteosarcoma, primary ABC, non-ossifying fibroma, chondroblastoma, brown tumor (hyperparathyroidism), giant cell reparative granuloma and the giant cell-rich type specifically exhibit much more distinction than GCTB. Recurrence in case of tumor posttreatment usually takes place after 3 years but, GCTs have shown late relapse such as 15 years of time span which occurs at the locus where surgical treatment was performed to eliminate the tumor [62,63].…”

Section: Giant Cell Tumor Of Bone (Gctb)mentioning

confidence: 99%

Role of cancer stem cells in the development of giant cell tumor of bone

et al. 2020

View full text Add to dashboard Cite

The primary bone tumor is usually observed in adolescence age group which has been shown to be part of nearly 20% of the sarcomas known today. Giant cell tumor of bone (GCTB) can be benign as well as malignant tumor which exhibits localized dynamism and is usually associated with the end point of a long bone. Giant cell tumor (GCT) involves mononuclear stromal cells which proliferate at a high rate, multinucleated giant cells and stromal cells are equally present in this type of tumor. Cancer stem cells (CSCs) have been confirmed to play a potential role in the development of GCT. Cancer stem cell-based microRNAs have been shown to contribute to a greater extent in giant cell tumor of bone. CSCs and microRNAs present in the tumors specifically are a great concern today which need indepth knowledge as well as advanced techniques to treat the bone cancer effectively. In this review, we attempted to summarize the role played by cancer stem cells involving certain important molecules/factors such as; Mesenchymal Stem Cells (MSCs), miRNAs and signaling mechanism such as; mTOR/PI3K-AKT, towards the formation of giant cell tumor of bone, in order to get an insight regarding various effective strategies and research advancements to obtain adequate knowledge related to CSCs which may help to focus on highly effective treatment procedures for bone tumors.

show abstract

“…Also, it has uncontrolled proliferation of mesenchymal stromal cells due to sustained osteoclastogenesis and failure of differentiation into osteoblasts 1, 2 . In general, these tumors are rare. A populationbased study from Sweden found an incidence rate of 1.3 per million persons per year 3 . The incidence of GCTB in Asian countries is significantly higher than that in western countries 4,5 .…”

Section: Introductionmentioning

confidence: 99%

“…The incidence of GCTB in Asian countries is significantly higher than that in western countries 4,5 . It is more common in the 20s and 30s age groups and there is a slight female predominance 3,[6][7][8] .…”

Section: Introductionmentioning

confidence: 99%

Outcome of Treatment of Giant-Cell Tumor of Bone: a Single-Institutional Retrospective Study

Elshenawy

Badran

Elshentenawy

et al. 2019

Kasr-Al-Aini J.of Clin. Onc. and Nuc. Med.

View full text Add to dashboard Cite

Background: Giant-cell tumor of bone (GCTB) is a locally aggressive tumor which metastasizes infrequently to the lungs. The standard treatment of GCTB was surgery until the approval of denosumab. Aim: To describe the outcome of treatment of this rare tumor and to determine factors that influence survival. Methods: Retrospective review of the medical records of GCTB patients treated at our institution. Collected data includes: clinicopathological data, treatment modalities and possible prognostic factors. Results: Forty-two patients were identified between May 2008 and November 2017. Their median age was 31 years, and the majority (62%) were females. The commonest primary sites were the upper and lower limbs (50% and 43%, respectively). Eight (19%) patients initially presented with lung metastases. Thirteen (31%) patients received denosumab as first line treatment before surgery and 12 of them underwent surgery post-denosumab. Denosumab was given after recurrence in 12 (29%) patients [8 (19%) with lung metastasis and 4 (10%) with localized disease]. The objective response rate to denosumab after recurrence was 50%. Four (10%) patients achieved complete response and 2 (5%) partial response. After a median follow up of 4.7 years, 6 (14%) patients had local recurrence and 8 (19%) had lung metastasis with no recorded deaths. The 5-year progression-free survival rate was 61%. Conclusion: Denosumab is effective and tolerable in the management of GCTB preoperatively in localized disease to facilitate surgery and in the management of metastatic disease. Multi-institutional prospective studies are needed for further assessment.

show abstract

Population-based study of giant cell tumor of bone in Sweden (1983–2011)

Cited by 43 publications

References 38 publications

Surveillance for lung metastasis from giant cell tumor of bone

Surveillance for lung metastasis from giant cell tumor of bone

Role of cancer stem cells in the development of giant cell tumor of bone

Outcome of Treatment of Giant-Cell Tumor of Bone: a Single-Institutional Retrospective Study

Contact Info

Product

Resources

About